Abstract PO1-06-02: Solti-1716 TATEN Phase II Trial: Targeting Non-Luminal Disease by PAM50 with Pembrolizumab and Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced Breast Cancer (ABC)
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined